ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.70378
0.14%
Brent Oil
83.385
0.22%
Bitcoin
65,332.58
0.14%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Enveric Biosciences Inc (ENVB)

  7. Enveric Biosciences Inc (ENVB) Noticias

ENVB

Enveric Biosciences (ENVB)

Enveric Biosciences Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ENVB
FechaHoraFuenteTítuloSímboloCompañía
15/05/202405:00Business WireEnveric Biosciences Reports First Quarter 2024 Financial and Corporate ResultsNASDAQ:ENVBEnveric Biosciences Inc
14/05/202407:00Business WireEnveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health DisordersNASDAQ:ENVBEnveric Biosciences Inc
08/05/202406:00Business WireEnveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using CannabinoidsNASDAQ:ENVBEnveric Biosciences Inc
26/03/202406:00Business WireEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023NASDAQ:ENVBEnveric Biosciences Inc
19/03/202406:00Business WireEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint DiseaseNASDAQ:ENVBEnveric Biosciences Inc
12/03/202406:00Business WireEnveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term SheetsNASDAQ:ENVBEnveric Biosciences Inc
11/03/202411:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ENVBEnveric Biosciences Inc
11/03/202407:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENVBEnveric Biosciences Inc
29/02/202406:00Business WireEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of CompoundsNASDAQ:ENVBEnveric Biosciences Inc
26/02/202415:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENVBEnveric Biosciences Inc
23/02/202407:00Business WireEnveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual PropertyNASDAQ:ENVBEnveric Biosciences Inc
21/02/202407:00Business WireEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health DisordersNASDAQ:ENVBEnveric Biosciences Inc
14/02/202414:36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ENVBEnveric Biosciences Inc
06/02/202409:17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ENVBEnveric Biosciences Inc
24/01/202407:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ENVBEnveric Biosciences Inc
22/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENVBEnveric Biosciences Inc
11/01/202415:43Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENVBEnveric Biosciences Inc
29/12/202307:52Business WireEnveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-MarketNASDAQ:ENVBEnveric Biosciences Inc
28/12/202307:00Business WireEnveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 SeriesNASDAQ:ENVBEnveric Biosciences Inc
27/12/202307:00Business WireEnveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373NASDAQ:ENVBEnveric Biosciences Inc
20/12/202307:00Business WireEnveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”NASDAQ:ENVBEnveric Biosciences Inc
06/12/202315:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ENVBEnveric Biosciences Inc
05/12/202307:00Business WireEnveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived CompoundsNASDAQ:ENVBEnveric Biosciences Inc
01/12/202315:31Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ENVBEnveric Biosciences Inc
29/11/202307:00Business WireEnveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin DerivativesNASDAQ:ENVBEnveric Biosciences Inc
27/11/202307:00Business WireEnveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal ChemistryNASDAQ:ENVBEnveric Biosciences Inc
24/11/202307:00Business WireEnveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)NASDAQ:ENVBEnveric Biosciences Inc
13/11/202315:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENVBEnveric Biosciences Inc
13/11/202315:01Business WireEnveric Biosciences Reports Third Quarter 2023 Corporate and Financial ResultsNASDAQ:ENVBEnveric Biosciences Inc
31/10/202307:00Business WireEnveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of PsilocinNASDAQ:ENVBEnveric Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:ENVB

Su Consulta Reciente

USOTC
PNXLF
Argentina Lithium and En... (QB)
NYSE
IQI
Invesco Quality Municipa...
BOV
MRVE3M
MRV ON
NASDAQI
CRSPMEV1
CRSP US Mega Cap Value
HUOB
SMTUSDT
SmartMesh
LSE
CE9G
Amundi Ms Exru
BIT
F19455
Vontobel Financial Produ...
EU
VTR
Vitura
LSE
IGWD
Ishr World G H
EU
DVOAQ
Departement du Val d Ois...
NASDAQ
FLTMQX
Banking Opportunity Port...
LSE
81LI
Higher Ed.1 B1s
BMF
DITV25
DITV25 - 10/2025
LSE
AJ75
City Stock.28
BIT
W83YE6
UBS
USOTC
CJPRF
Central Japan Railway (PK)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados